MCID: NNL001
MIFTS: 37

Non-Langerhans-Cell Histiocytosis

Categories: Immune diseases, Rare diseases

Aliases & Classifications for Non-Langerhans-Cell Histiocytosis

MalaCards integrated aliases for Non-Langerhans-Cell Histiocytosis:

Name: Non-Langerhans-Cell Histiocytosis 12 54 15
Histiocytosis, Non-Langerhans-Cell 77 54 45 74

Classifications:



External Ids:

Disease Ontology 12 DOID:4330
MeSH 45 D015616
UMLS 74 C0019624

Summaries for Non-Langerhans-Cell Histiocytosis

MalaCards based summary : Non-Langerhans-Cell Histiocytosis, also known as histiocytosis, non-langerhans-cell, is related to juvenile xanthogranuloma and erdheim-chester disease. An important gene associated with Non-Langerhans-Cell Histiocytosis is CD163 (CD163 Molecule), and among its related pathways/superpathways are Hematopoietic cell lineage and Dendritic Cells Developmental Lineage Pathway. The drugs Mycophenolic acid and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include t cells, liver and skin.

Wikipedia : 77 Non-Langerhans cell histiocytosis refers to a family of histiocytosis characterized by the absence of... more...

Related Diseases for Non-Langerhans-Cell Histiocytosis

Diseases related to Non-Langerhans-Cell Histiocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Related Disease Score Top Affiliating Genes
1 juvenile xanthogranuloma 33.0 DES F13A1
2 erdheim-chester disease 32.7 SERPINA3 SST
3 reticulohistiocytic granuloma 32.3 CD163 SERPINA3
4 langerhans cell histiocytosis 31.2 CD163 CD1A F13A1
5 histiocytosis 31.0 CD163 CD1A SERPINA3
6 fibromatosis 30.4 ACTC1 DES
7 histiocytoma 30.4 CD163 SERPINA3
8 fibroblastic rheumatism 29.8 ACTC1 CD163 DES F13A1
9 histiocytosis, progressive mucinous 11.5
10 lipogranulomatosis 10.5
11 leiomyosarcoma 10.2 ACTC1 DES
12 ovarian fibrothecoma 10.2 ACTC1 DES
13 cutaneous leiomyosarcoma 10.2 ACTC1 DES
14 botryoid rhabdomyosarcoma 10.2 ACTC1 DES
15 spindle cell lipoma 10.2 ACTC1 DES
16 glomangioma 10.2 ACTC1 DES
17 parachordoma 10.2 ACTC1 DES
18 syringocystadenoma papilliferum 10.2 ACTC1 DES
19 ossifying fibromyxoid tumor 10.2 ACTC1 DES
20 progressive nodular histiocytosis 10.2 ACTC1 F13A1
21 benign metastasizing leiomyoma 10.2 ACTC1 DES
22 leiomyoma 10.2 ACTC1 DES
23 scleromyxedema 10.2 ACTC1 F13A1
24 pulmonary vein stenosis 10.2 ACTC1 DES
25 perivascular epithelioid cell tumor 10.2 ACTC1 DES
26 congenital fibrosarcoma 10.2 ACTC1 DES
27 langerhans cell sarcoma 10.2 CD163 CD1A
28 ischemic fasciitis 10.2 ACTC1 DES
29 fasciitis 10.2 ACTC1 DES
30 reticulum cell sarcoma 10.2 ACTC1 DES
31 pseudosarcomatous fibromatosis 10.2 ACTC1 DES
32 dedifferentiated liposarcoma 10.2 ACTC1 DES
33 alk+ histiocytosis 10.2 CD1A F13A1
34 glomus tumor 10.2 ACTC1 DES
35 spindle cell sarcoma 10.2 ACTC1 DES
36 smooth muscle tumor 10.1 ACTC1 DES
37 dermis tumor 10.1 CD163 SERPINA3
38 infantile myofibromatosis 10.1 ACTC1 DES
39 chondromyxoid fibroma 10.1 ACTC1 DES
40 rhabdoid tumor predisposition syndrome 1 10.1 ACTC1 DES
41 kawasaki disease 10.1
42 dermatitis 10.1
43 rosai-dorfman disease 10.1
44 xanthoma disseminatum 10.1
45 headache 10.1
46 benign cephalic histiocytosis 10.1
47 generalized eruptive histiocytosis 10.1
48 angiomyolipoma 10.1 ACTC1 DES
49 intravascular papillary endothelial hyperplasia 10.1 ACTC1 SERPINA3
50 spindle cell carcinoma 10.1 ACTC1 DES

Graphical network of the top 20 diseases related to Non-Langerhans-Cell Histiocytosis:



Diseases related to Non-Langerhans-Cell Histiocytosis

Symptoms & Phenotypes for Non-Langerhans-Cell Histiocytosis

Drugs & Therapeutics for Non-Langerhans-Cell Histiocytosis

Drugs for Non-Langerhans-Cell Histiocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
2
Methotrexate Approved Phase 3,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
3
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
4
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Not Applicable 6055-19-2, 50-18-0 2907
5
Hydrocortisone acetate Approved, Vet_approved Phase 3,Phase 2 50-03-3
6
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
7
Etoposide Approved Phase 3,Phase 2,Not Applicable 33419-42-0 36462
8
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 5754
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
10
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
11
leucovorin Approved Phase 3,Phase 2,Not Applicable 58-05-9 6006 143
12
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
13
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
14
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
15
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
16
Miglustat Approved Phase 3,Phase 2,Phase 1 72599-27-0 51634
17
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
18
Pegaspargase Approved, Investigational Phase 3 130167-69-0
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Not Applicable 59-30-3 6037
20
Prednisolone hemisuccinate Experimental Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
21
1-Deoxynojirimycin Experimental, Investigational Phase 3,Phase 2 19130-96-2 1374
22
Doxil Approved June 1999 Phase 3,Phase 2 31703
23 Hydrocortisone 17-butyrate 21-propionate Phase 3,Phase 2
24 Hydrocortisone-17-butyrate Phase 3,Phase 2
25 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
26 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
27 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
29 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
30 Etoposide phosphate Phase 3,Phase 2,Not Applicable
31 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
32 Vitamin B Complex Phase 3,Phase 2,Not Applicable
33 Anti-Infective Agents Phase 3,Phase 1,Phase 2,Not Applicable
34 Autonomic Agents Phase 3,Phase 2,Phase 1,Not Applicable
35 BB 1101 Phase 3,Phase 2,Phase 1,Not Applicable
36 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
37 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
38 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1,Not Applicable
39 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
40 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
41 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Not Applicable
42 Topoisomerase Inhibitors Phase 3,Phase 2,Not Applicable
43 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
44 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
45 Antiemetics Phase 3,Phase 2,Phase 1,Not Applicable
46 Antitubercular Agents Phase 3,Phase 2
47 Vitamin B9 Phase 3,Phase 2,Not Applicable
48 Folate Phase 3,Phase 2,Not Applicable
49 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Not Applicable
50 Cyclosporins Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 96)
# Name Status NCT ID Phase Drugs
1 Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology Unknown status NCT02862054 Phase 2, Phase 3
2 Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis Unknown status NCT00334672 Phase 3 busulfan;cyclophosphamide;cyclosporine;dexamethasone;etoposide;methotrexate;mycophenolate mofetil;therapeutic hydrocortisone
3 Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004 Completed NCT00426101 Phase 3 Dexamethasone;Etoposide;Cyclosporin
4 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
5 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
6 DEP-Ru Regimen as a Salvage Therapy for HLH Recruiting NCT03533790 Phase 3 DEP-Ru
7 Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis Recruiting NCT03312751 Phase 3 Emapalumab
8 L-DEP as an Initial Treatment for EBV-HLH Recruiting NCT02912702 Phase 3 Pegaspargase;doxorubicin hydrochloride liposome injection;etoposide;methylprednisolone;Etoposide;dexamethasone
9 L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis Recruiting NCT02631109 Phase 3 Pegaspargase;doxorubicin;etoposide;methylprednisolone
10 A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis Active, not recruiting NCT01818492 Phase 2, Phase 3
11 Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C Active, not recruiting NCT02612129 Phase 2, Phase 3 arimoclomol;Placebo
12 Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease Active, not recruiting NCT02534844 Phase 2, Phase 3 VTS-270;Sham Procedure Control
13 Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Active, not recruiting NCT02004691 Phase 2, Phase 3 placebo (saline);GZ402665
14 Etoposide in the First-line Treatment of Adult EBV-HLH Not yet recruiting NCT03742115 Phase 3 Etoposide;Dexamethasone;Etoposide;IVIG
15 Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1 Not yet recruiting NCT03879655 Phase 2, Phase 3 VTS-270
16 T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders Terminated NCT00176826 Phase 2, Phase 3 Myeloablative conditioning regimen
17 Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease Completed NCT02281760 Phase 2 Dabrafenib Mesylate;Trametinib Dimethyl Sulfoxide
18 Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis Completed NCT01104025 Phase 2 ATG, rabbit;Etoposide;Methotrexate;hydrocortisone;Dexamethasone
19 Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 Completed NCT02124083 Phase 1, Phase 2 Vorinostat
20 Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204) Completed NCT01998633 Phase 2
21 Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine Completed NCT00975689 Phase 1, Phase 2 N-Acetyl Cysteine
22 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
23 Miglustat in Niemann-Pick Type C Disease Completed NCT00517153 Phase 2 miglustat
24 Stem Cell Transplant for Immunologic or Histiocytic Disorders Completed NCT00176865 Phase 2 Fludarabine;Melphalan;Anti-thymocyte globulin (ATG);Campath 1H;Cyclosporin A;Mycophenolate mofetil;Intravenous immunoglobulin (IVIG)
25 Ruxolitinib Combined With Dexamethasone for HLH Recruiting NCT03795909 Phase 1, Phase 2 Ruxolitinib;Dexamethasone
26 Treatment of Familiar Lymphohistiocytosis Recruiting NCT02472054 Phase 1, Phase 2 Alemtuzumab;Methyl Prednisolone (MP);Cyclosporin A (CSA)
27 Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis Recruiting NCT02385110 Phase 2 Alemtuzumab;Etoposide;Dexamethasone;Methotrexate;Tocilizumab
28 Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH) Recruiting NCT02007239 Phase 2 tocilizumab
29 A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome Recruiting NCT02400463 Phase 2 Ruxolitinib
30 Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1 Recruiting NCT03887533 Phase 1, Phase 2 VTS-270
31 Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Recruiting NCT03513328 Phase 1, Phase 2 Thiotepa--single daily dose;Thiotepa--escalated dose
32 Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C Recruiting NCT03471143 Phase 1, Phase 2 2-Hydroxypropyl-Beta-Cyclodextrin
33 A Study to Investigate the Safety and Efficacy of an Anti-IFN-gamma mAb in Children With Systemic Juvenile Idiopathic Arthritis (sJIA) Developing Macrophage Activation Syndrome/ Secondary Hemophagocytic Lymphohistiocytosis (MAS/sHLH) Recruiting NCT03311854 Phase 2 NI-0501
34 Study of Lithium Carbonate to Treat Niemann-Pick Type C1 Disease Recruiting NCT03201627 Phase 1, Phase 2 Lithium Carbonate
35 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Ulixertinib;Vemurafenib
36 Safety and Efficacy of Intravenous Trappsol Cyclo (HPBCD) in Niemann-Pick Type C Patients Recruiting NCT02912793 Phase 1, Phase 2 Hydroxypropyl-beta-cyclodextrin
37 Immune Disorder HSCT Protocol Recruiting NCT01821781 Phase 2 Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
38 T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Recruiting NCT00368355 Phase 2 Ara-C;Cyclophosphamide
39 Trial of DA-EPOCH Regimen for NHL With HLH Active, not recruiting NCT01818908 Phase 2 DA-EPOCH
40 A Study of Lenalidomide for Adult Histiocyte Disorders Active, not recruiting NCT02523040 Phase 2 Lenalidomide
41 Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency Active, not recruiting NCT02292654 Phase 1, Phase 2 Olipudase alfa
42 Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders Active, not recruiting NCT01372228 Phase 1, Phase 2
43 A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Enrolling by invitation NCT02004704 Phase 2 GZ402665
44 Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations Not yet recruiting NCT03794297 Phase 2 Dabrafenib Mesylate;Trametinib Dimethyl Sulfoxide
45 N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC) Not yet recruiting NCT03759639 Phase 2 IB1001
46 Safety and Tolerability Study of VTS-270 in Pediatric Participants With Niemann-Pick Type C (NPC) Disease Not yet recruiting NCT03687476 Phase 2 VTS-270
47 Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease Terminated NCT01727206 Phase 2 Tocilizumab
48 Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism Terminated NCT00668564 Phase 2 Cyclophosphamide;Campath-1H;Busulfan
49 Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease Completed NCT01747135 Phase 1 VTS-270
50 Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients Completed NCT01722526 Phase 1 Recombinant human acid sphingomyelinase

Search NIH Clinical Center for Non-Langerhans-Cell Histiocytosis

Cochrane evidence based reviews: histiocytosis, non-langerhans-cell

Genetic Tests for Non-Langerhans-Cell Histiocytosis

Anatomical Context for Non-Langerhans-Cell Histiocytosis

MalaCards organs/tissues related to Non-Langerhans-Cell Histiocytosis:

42
T Cells, Liver, Skin, Brain, Bone, Eye, Bone Marrow

Publications for Non-Langerhans-Cell Histiocytosis

Articles related to Non-Langerhans-Cell Histiocytosis:

(show all 27)
# Title Authors Year
1
A Rare Case of Erdheim-Chester Disease (Non-Langerhans Cell Histiocytosis) with Concurrent Langerhans Cell Histiocytosis: A Diagnostic and Therapeutic Challenge. ( 29888013 )
2018
2
High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. ( 28679734 )
2017
3
Non-Langerhans cell histiocytosis. ( 26739442 )
2016
4
Spontaneous regression of infantile dural-based non-Langerhans cell histiocytosis after surgery: case report. ( 25634822 )
2015
5
[Erdheim-Chester disease and Rosai-Dorfman disease: Pathological, radiological and clinical features of adult non-Langerhans cell histiocytosis]. ( 26305142 )
2015
6
Suprasellar non-Langerhans cell histiocytosis (Erdheim-Chester disease)--a case report. ( 23465991 )
2013
7
Retinal manifestations in a patient with xanthoma disseminatum (non-langerhans cell histiocytosis). ( 21484660 )
2011
8
Rare case of infratentorial non-Langerhans cell histiocytosis with lethal outcome presenting multiple diagnostic difficulties. ( 22025140 )
2011
9
Non-Langerhans cell histiocytosis with isolated CNS involvement: an unusual variant of Erdheim-Chester disease. ( 20337948 )
2010
10
Intracranial non-Langerhans cell histiocytosis presenting as an isolated intraparenchymal lesion. ( 20635081 )
2010
11
Fibroblastic rheumatism: fibromatosis rather than non-Langerhans cell histiocytosis. ( 19615014 )
2010
12
Endolymphatic non-langerhans cell histiocytosis of the larynx: report of an uncommon disease manifestation. ( 20463609 )
2010
13
Non-Langerhans cell histiocytosis in a child with Kawasaki disease. ( 21686403 )
2009
14
Diffuse xanthogranulomatous dermatitis and systemic Langerhans cell histiocytosis: A novel case that demonstrates bridging between non-Langerhans cell histiocytosis and Langerhans cell histiocytosis. ( 19022530 )
2009
15
Cerebral non-Langerhans cell histiocytosis in a 17-year-old patient with a headache: case report. ( 19363626 )
2009
16
Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. ( 16020507 )
2005
17
[Erdheim-Chester disease: a non-Langerhans cell histiocytosis. A clinical-case and review of the literature]. ( 15344569 )
2004
18
Progressive histiocytosis: description of a case of slow-course non-Langerhans cell histiocytosis. ( 12399681 )
2002
19
Problems in differential diagnosis of non Langerhans cell histiocytosis with pituitary involvement: case report and review of literature. ( 12665654 )
2002
20
A child with both Langerhans and non-Langerhans cell histiocytosis. ( 12383099 )
2002
21
Primary cerebral non-Langerhans cell histiocytosis: MRI and differential diagnosis. ( 12221448 )
2002
22
Benign cephalic histiocytosis progressing into juvenile xanthogranuloma: a non-Langerhans cell histiocytosis transforming under the influence of a virus? ( 10698221 )
2000
23
Non-Langerhans cell histiocytosis associated with lymphocyte-predominant Hodgkin's disease. ( 10564322 )
1999
24
Generalized non-Langerhans cell histiocytosis: four cases illustrate a spectrum of disease. ( 7737766 )
1995
25
An unusual case of non-Langerhans cell histiocytosis. ( 8294600 )
1994
26
A unique non-Langerhans cell histiocytosis with some features of generalized eruptive histiocytoma. ( 8034797 )
1994
27
Congenital self-healing non-Langerhans cell histiocytosis. ( 3058480 )
1988

Variations for Non-Langerhans-Cell Histiocytosis

Expression for Non-Langerhans-Cell Histiocytosis

Search GEO for disease gene expression data for Non-Langerhans-Cell Histiocytosis.

Pathways for Non-Langerhans-Cell Histiocytosis

Pathways related to Non-Langerhans-Cell Histiocytosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.14 CD1A CD1E
2 10.82 CD163 CD1A
3 10.48 ACTC1 DES

GO Terms for Non-Langerhans-Cell Histiocytosis

Cellular components related to Non-Langerhans-Cell Histiocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet alpha granule lumen GO:0031093 8.96 F13A1 SERPINA3
2 blood microparticle GO:0072562 8.8 ACTC1 F13A1 SERPINA3

Biological processes related to Non-Langerhans-Cell Histiocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 muscle filament sliding GO:0030049 9.32 ACTC1 DES
2 acute-phase response GO:0006953 9.26 CD163 SERPINA3
3 positive regulation of T cell mediated cytotoxicity GO:0001916 9.16 CD1A CD1E
4 antigen processing and presentation, exogenous lipid antigen via MHC class Ib GO:0048007 8.96 CD1A CD1E
5 antigen processing and presentation, endogenous lipid antigen via MHC class Ib GO:0048006 8.62 CD1A CD1E

Molecular functions related to Non-Langerhans-Cell Histiocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipopeptide binding GO:0071723 9.16 CD1A CD1E
2 endogenous lipid antigen binding GO:0030883 8.96 CD1A CD1E
3 exogenous lipid antigen binding GO:0030884 8.62 CD1A CD1E

Sources for Non-Langerhans-Cell Histiocytosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....